Brian Eastwood1, John Strang2, John Marsden3. 1. Addictions Department, Box 48, Institute of Psychiatry, Psychology and Neuroscience, DeCrespigny Park, Denmark Hill, London SE5 8AF, United Kingdom; Alcohol, Drugs and Tobacco Division, Health and Wellbeing Directorate, Public Health England, 2nd Floor, Skipton House, 80 London Road, London SE1 6LH, United Kingdom. Electronic address: Brian.Eastwood@phe.gov.uk. 2. Addictions Department, Box 48, Institute of Psychiatry, Psychology and Neuroscience, DeCrespigny Park, Denmark Hill, London SE5 8AF, United Kingdom. Electronic address: john.strang@kcl.ac.uk. 3. Addictions Department, Box 48, Institute of Psychiatry, Psychology and Neuroscience, DeCrespigny Park, Denmark Hill, London SE5 8AF, United Kingdom; Alcohol, Drugs and Tobacco Division, Health and Wellbeing Directorate, Public Health England, 2nd Floor, Skipton House, 80 London Road, London SE1 6LH, United Kingdom.
Abstract
BACKGROUND: This the first 5-year effectiveness study of publicly funded treatment for opioid use disorder (OUD) in England. METHODS: All adults initiating treatment in 2008/09 in all 149 local treatment systems reporting to the National Drug Treatment Monitoring System (n=54,347). Admission polydrug use sub-populations were identified by Latent Class Analysis. The treatment outcome measure was 'successful completion and no re-presentation within six months' (SCNR) analysed by multilevel, multivariable logistic regression and funnel plots to contrast outcome by treatment system. RESULTS: SCNR was achieved by 21.9%. Heroin and crack cocaine users were significantly less likely to achieve this outcome than patients who used heroin only (adjusted odds ratio [AOR] 0.90; 95% confidence interval [CI] 0.85-0.95). Older patients (AOR 1.09; CI 1.07-1.11), those employed (AOR 1.27; CI 1.18-1.37) and those enrolled for longer treatment were more likely to achieve the outcome measure. After risk adjustment, the local treatment systems that achieved substantially better outcome performance (14/149) had a lower rate of opiate prevalence in the local population at time of study initiation (incidence rate difference [IRD] 4.1; CI 4.0-4.2), fewer criminal offences per thousand (IRD 28.5; CI 28.1-28.8) and lower drug-related deaths per million (IRD 5.9; CI 5.9-5.9). CONCLUSIONS: In an English national study, one fifth of patients successful completed treatment for OUD and did not present for further treatment within six months. Longer time in treatment increases the probability of achieving and maintaining clinical benefit from treatment. After risk-adjustment, an important minority of treatment systems achieve substantially better outcome performance. Crown
BACKGROUND: This the first 5-year effectiveness study of publicly funded treatment for opioid use disorder (OUD) in England. METHODS: All adults initiating treatment in 2008/09 in all 149 local treatment systems reporting to the National Drug Treatment Monitoring System (n=54,347). Admission polydrug use sub-populations were identified by Latent Class Analysis. The treatment outcome measure was 'successful completion and no re-presentation within six months' (SCNR) analysed by multilevel, multivariable logistic regression and funnel plots to contrast outcome by treatment system. RESULTS: SCNR was achieved by 21.9%. Heroin and crack cocaine users were significantly less likely to achieve this outcome than patients who used heroin only (adjusted odds ratio [AOR] 0.90; 95% confidence interval [CI] 0.85-0.95). Older patients (AOR 1.09; CI 1.07-1.11), those employed (AOR 1.27; CI 1.18-1.37) and those enrolled for longer treatment were more likely to achieve the outcome measure. After risk adjustment, the local treatment systems that achieved substantially better outcome performance (14/149) had a lower rate of opiate prevalence in the local population at time of study initiation (incidence rate difference [IRD] 4.1; CI 4.0-4.2), fewer criminal offences per thousand (IRD 28.5; CI 28.1-28.8) and lower drug-related deaths per million (IRD 5.9; CI 5.9-5.9). CONCLUSIONS: In an English national study, one fifth of patients successful completed treatment for OUD and did not present for further treatment within six months. Longer time in treatment increases the probability of achieving and maintaining clinical benefit from treatment. After risk-adjustment, an important minority of treatment systems achieve substantially better outcome performance. Crown
Authors: Laura R Lander; Wanhong Zheng; Jeremy D Hustead; James J Mahoney; James H Berry; Patrick Marshalek; Erin L Winstanley Journal: J Neurol Sci Date: 2020-02-03 Impact factor: 3.181
Authors: Tea Rosic; Leen Naji; Balpreet Panesar; Darren B Chai; Nitika Sanger; Brittany B Dennis; David C Marsh; Launette Rieb; Andrew Worster; Lehana Thabane; Zainab Samaan Journal: BMJ Open Date: 2021-01-12 Impact factor: 2.692
Authors: Emmert Roberts; Matthew Hotopf; John Strang; John Marsden; Martin White; Brian Eastwood; Colin Drummond Journal: Lancet Reg Health Eur Date: 2021-04
Authors: Kim Corace; Kelly Suschinsky; Jennifer Wyman; Pamela Leece; Sue Cragg; Sarah Konefal; Priscille Pana; Susan Barrass; Amy Porath; Brian Hutton Journal: Int J Drug Policy Date: 2021-12-23
Authors: Miranda G Greiner; Matisyahu Shulman; Tse-Hwei Choo; Jennifer Scodes; Martina Pavlicova; Aimee N C Campbell; Patricia Novo; Marc Fishman; Joshua D Lee; John Rotrosen; Edward V Nunes Journal: J Subst Abuse Treat Date: 2021-04-30
Authors: John Marsden; Camille Goetz; Tim Meynen; Luke Mitcheson; Garry Stillwell; Brian Eastwood; John Strang; Nick Grey Journal: EBioMedicine Date: 2018-02-02 Impact factor: 8.143
Authors: Darren Chai; Tea Rosic; Balpreet Panesar; Nitika Sanger; Emma A van Reekum; David C Marsh; Andrew Worster; Lehana Thabane; Zainab Samaan Journal: JAMA Netw Open Date: 2021-08-02